Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus PENBRITIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus PENBRITIN S.
DYCILL vs PENBRITIN-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic